Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 11/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.56 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.56 |
| ▸ | NFE2 | Q16621 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012616 | 0.90 | MAPK13 (0.66) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL1013743 | 0.89 | MAPK14 (0.73) | MAPK13MAPK12MAPK11MAPK14NTRK1 | |
| SCHEMBL378957 | 0.89 | MAPK14 (0.68) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL1013690 | 0.88 | MAPK13 (0.59) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL1793950 | 0.87 | MAPK14 (0.58) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL1012997 | 0.87 | MAPK14 (0.66) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| Carbamic Acid SCHEMBL1780358 | 0.87 | MAPK13 (0.62) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL4226618 | 0.86 | CDK8 (0.63) | MAPK13MAPK12MAPK11MAPK14NTRK1 | |
| SCHEMBL1013422 | 0.86 | MAPK13 (0.69) | MAPK13MAPK12MAPK11MAPK14JAK2 | |
| SCHEMBL17449180 | 0.85 | MAPK13 (0.58) | MAPK13MAPK12MAPK11MAPK14JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207166-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207166-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207166-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| EP-1751139-B1 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1751139-B1 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110136809-A1 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136809-A1 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-7838524-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838524-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
| EP-1960394-A2 | PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Bayer HealthCare AG (DE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007059202-A2 | PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE AG (DE) | 2007-05-24 | — | — | WO | disclosed |
| EP-1751139-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Bayer Pharmaceuticals Corporation (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | UMPS, SLC14A1, TP53 | MAPK13 3031/4885MAPK12 3110/4885MAPK11 2481/4885 |
| US-20110136809-A1 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer | UMPS, SLC14A1, TP53 | MAPK13 3031/4885MAPK12 3110/4885MAPK11 2481/4885 |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | UMPS, SLC14A1, CPS1 | MAPK13 3641/4885MAPK12 4114/4885MAPK11 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.